Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All probiotics studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchProbioticsProbiotics (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Case 98% Improvement Relative Risk Probiotics  Di Pierro et al.  Prophylaxis  RCT Do probiotics reduce COVID-19 infections? RCT 128 patients in Italy (September - December 2020) Fewer cases with probiotics (p<0.000001) c19early.org Di Pierro et al., Minerva Medica, March 2021 Favors probiotics Favors control

The administration of S. salivarius K12 to children may reduce the rate of SARS-CoV-2 infection

Di Pierro et al., Minerva Medica, doi:10.23736/S0026-4806.21.07487-5
Mar 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Probiotics for COVID-19
17th treatment shown to reduce risk in March 2021
 
*, now known with p = 0.0000013 from 26 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19early.org
Interim report on an RCT for prophylactic treatment with S. salivarius K12, showing significantly lower cases with treatment. Only patients with symptoms or known positive contacts were tested. Trial identification/registration details are not provided.
The immune effects of probiotics are strain-specific.
risk of case, 98.0% lower, RR 0.02, p < 0.001, treatment 0 of 64 (0.0%), control 24 of 64 (37.5%), NNT 2.7, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Di Pierro et al., 12 Mar 2021, Randomized Controlled Trial, Italy, peer-reviewed, 2 authors, study period September 2020 - December 2020.
This PaperProbioticsAll
Abstract: © This document is protected by international copyright laws. No additional reproduction is authorized. It is permitted for personal use to download and save only one file and print only one copy of this Article. It is not permitted to make additional copies (either sporadically or systematically, either printed or electronic) of the Article for any purpose. It is not permitted to distribute the electronic copy of the article through online internet and/or intranet file sharing systems, electronic mailing or any other means which may allow access to the Article. The use of all or any part of the Article for any Commercial Use is not permitted. The creation of derivative works from the Article is not permitted. The production of reprints for personal or commercial use is not permitted. It is not permitted to remove, cover, overlay, obscure, block, or change any copyright notices or terms of use which the Publisher may post on the Article. It is not permitted to frame or use framing techniques to enclose any trademark, logo, or other proprietary information of the Publisher. COPYRIGHT 2021 EDIZIONI MINERVA MEDICA LETTERS TO THE EDITOR © 2021 EDIZIONI MINERVA MEDICA Online version at http://www.minervamedica.it Minerva Medica 2021 August;112(4):514-6 DOI: 10.23736/S0026-4806.21.07487-5 The administration of S. salivarius K12 to children may reduce the rate of SARS-CoV-2 infection The Coronavirus disease 2019 (COVID-19) pandemic, provoked by the worldwide spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused millions of infections and deaths worldwide since its emergence at the end of 2019. Unfortunately, natural immunity does not exist within the human population and no effective drug has been found thus far specifically for the disease. Incredibly, scientists from all over the world have developed some effective vaccines at an unprecedented pace.1 Unfortunately, vaccine manufacturing and distribution are two important bottlenecks. For this reason, vaccination schedules are proceeding more slowly than they should and was perhaps expected. While waiting for the current vaccination campaigns to produce the herd effect desired by each individual country, COVID-19 research has produced new lines of scientific thought. For instance, recent evidence showed the possible relationship between the lung and oral microbiotas. Indeed, analysis of the bronchoalveolar lavage fluid (BALF) of COVID-19 patients revealed the presence of elevated levels of oral and upper respiratory commensal bacteria.2 Anatomical and physiological considerations indicate that the oral cavity is the primary source of the lung microbiota community, acquired via aspiration and inhalation.3 Indeed, the microbiota of the lungs overlaps with that found in the mouth. In humans, the prominent taxa in BALF samples include mainly Streptococcus, Prevotella and Veillonella, and these are indeed detected in concurrently collected oral samples. Recent studies have shown that the microbiota in the lungs contributes to immunological homeostasis and can potentially alter susceptibility to viral infection.4 With respect to COVID-19, a particular abundance of Prevotella and Veillonella spp. in the lung microbiota composition has been observed in patients with SARS-CoV-2 pneumonia.5 A report by Iebba et al.6 (not yet peer-reviewed) profiled the oral microbiota of healthy controls and COVID-19-hospitalized patients, discovering the existence of four..
{ 'DOI': '10.23736/s0026-4806.21.07487-5', 'ISSN': ['0026-4806', '1827-1669'], 'URL': 'http://dx.doi.org/10.23736/S0026-4806.21.07487-5', 'author': [ {'affiliation': [], 'family': 'DI PIERRO', 'given': 'Francesco', 'sequence': 'first'}, {'affiliation': [], 'family': 'COLOMBO', 'given': 'Maria', 'sequence': 'additional'}], 'container-title': 'Minerva Medica', 'container-title-short': 'Minerva Med', 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2021, 7, 16]], 'date-time': '2021-07-16T09:27:49Z', 'timestamp': 1626427669000}, 'deposited': { 'date-parts': [[2021, 7, 16]], 'date-time': '2021-07-16T09:29:31Z', 'timestamp': 1626427771000}, 'indexed': {'date-parts': [[2024, 2, 7]], 'date-time': '2024-02-07T11:25:07Z', 'timestamp': 1707305107765}, 'is-referenced-by-count': 9, 'issue': '4', 'issued': {'date-parts': [[2021, 7]]}, 'journal-issue': {'issue': '4'}, 'link': [ { 'URL': 'https://www.minervamedica.it/pdf.php?cod=R10Y2021N04A0514', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '17149', 'original-title': [], 'prefix': '10.23736', 'published': {'date-parts': [[2021, 7]]}, 'published-print': {'date-parts': [[2021, 7]]}, 'publisher': 'Edizioni Minerva Medica', 'reference': [ { 'DOI': '10.1016/S1473-3099(20)30773-8', 'doi-asserted-by': 'publisher', 'key': '10.23736/S0026-4806.21.07487-5_ref001'}, { 'DOI': '10.1093/cid/ciaa203', 'doi-asserted-by': 'publisher', 'key': '10.23736/S0026-4806.21.07487-5_ref002'}, { 'DOI': '10.1007/s11427-017-9151-1', 'doi-asserted-by': 'publisher', 'key': '10.23736/S0026-4806.21.07487-5_ref003'}, { 'DOI': '10.1038/ncomms3106', 'doi-asserted-by': 'publisher', 'key': '10.23736/S0026-4806.21.07487-5_ref004'}, { 'DOI': '10.1093/bioinformatics/btaa285', 'doi-asserted-by': 'publisher', 'key': '10.23736/S0026-4806.21.07487-5_ref005'}, { 'DOI': '10.1101/2020.12.13.422589', 'doi-asserted-by': 'publisher', 'key': '10.23736/S0026-4806.21.07487-5_ref006'}, { 'DOI': '10.23736/S0026-4806.20.06570-2', 'doi-asserted-by': 'publisher', 'key': '10.23736/S0026-4806.21.07487-5_ref007'}], 'reference-count': 7, 'references-count': 7, 'relation': {}, 'resource': {'primary': {'URL': 'https://www.minervamedica.it/index2.php?show=R10Y2021N04A0514'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['General Medicine'], 'subtitle': [], 'title': 'The administration of S. salivarius K12 to children may reduce the rate of SARS-CoV-2 infection', 'type': 'journal-article', 'volume': '112'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit